ArticleIEEE sensors journal2021
Handheld Thermo-Photonic Device for Rapid, Low-Cost, and On-Site Detection and Quantification of Anti-SARS-CoV-2 Antibody.
Article in IEEE sensors journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Development and application of a smartphone-based thermal contrast amplification reader for photothermal lateral flow immunoassays.Microsystems & nanoengineering · 2026Article
- Enhancing Sensitivity of Commercial Gold Nanoparticle-Based Lateral Flow Assays: A Comparative Study of Colorimetric and Photothermal Approaches.Sensors (Basel, Switzerland) · 2025Article
- Rapid Detection of SARS-CoV-2 Based on the LAMP Assay Associated with the CRISPRCas12a System.Diagnostics (Basel, Switzerland) · 2023Article
- Polydopamine Nanoparticles-Based Three-Line Lateral Flow Immunoassay for COVID-19 Detection.Biosensors · 2023Article
- Handheld, Low-Cost, Aptamer-Based Sensing Device for Rapid SARS-CoV-2 RNA Detection Using Novelly Synthesized Gold Nanoparticles.IEEE sensors journal · 2022Article
- Rapid and Low-Cost Detection and Quantification of SARS-CoV-2 Antibody Titers of ICU Patients with Respiratory Deterioration Using a Handheld Thermo-Photonic Device.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence of vaccines and antibody therapeutics, rapid and scalable platforms are needed to quantify the antibody response of individuals. Lateral flow immunoassay (LFA) based test strips provide a rapid, low-cost, and point-of-care approach to antibody testing against the SARS-CoV-2 virus. These convenient and scalable tests, however, are qualitative in nature and cannot quantify the immune response of the infected and/or vaccinated individuals. This study reports on the development of a rapid, low cost and portable thermo-photonic device that enables sensitive detection and quantification of antibody levels using commercially available COVID-19 Antibody LFAs. Unlike conventional LFA readers, the developed technology is based on sensing the infrared thermal radiation of tag gold nanoparticles following laser excitation (aka photothermal response). Our proof-of-concept results with humanized monoclonal anti-SARS-CoV-2 Spike receptor-binding domain (RBD) IgG demonstrate that the thermo-photonic technology can detect and quantify antibody concentrations within the clinically relevant range and with a limit of detection of [Formula: see text]/ml. The reader in conjunction with antibody LFAs offers a low-cost, portable, and scalable solution for assessment of the degree of immunity in populations, quality control of convalescent plasma donations for antibody therapeutics, and monitoring the immune response of infected individuals and vaccine recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.